Wednesday, July 8, 2026

Drug profile · INN

cycloserine

cycloserine (SEROMYCIN) is a alanine racemase inhibitor. Associated with Sana Biotechnology. Route of administration: oral. Current US regulatory status: approved.

FDA: approved
US status approved
Patents linked 20
Pipeline programs 11
News articles 0
Drug details — cycloserine
US status
approved
Class
Route
ORAL
Patents
20
Programs
11
Data quality
0.89

Quick answer

cycloserine (SEROMYCIN) is a alanine racemase inhibitor. Associated with Sana Biotechnology. Route of administration: oral. Current US regulatory status: approved.

Key facts

INN cycloserine
Brand SEROMYCIN
Mechanism Alanine racemase inhibitor
Target Alanine racemase
Route ORAL
Formulation CAPSULE

Mechanism of action

Alanine racemase inhibitor

Primary target: Alanine racemase

Approval history

Authority Status Date
FDA approved

Pipeline programs

  1. D-cycloserine Phase 3 · United Therapeutics Europe · Autistic Disorder
  2. DCS (D-Cycloserine ) + Prolonged Imaginal Exposure Phase 3 · United Therapeutics Europe · Post Traumatic Stress Disorder
  3. Cycloserine Phase 2 · BRIGHT MINDS BIOSCIENCES · Opioid-Related Disorders
  4. D-Cycloserine Phase 2 · BRIGHT MINDS BIOSCIENCES · Smoking Cessation
  5. D-Cycloserine (DCS) Phase 2 · BRIGHT MINDS BIOSCIENCES · Cocaine Use Disorders
  6. D-cycloserine Phase 2 · BRIGHT MINDS BIOSCIENCES · Substance-Related Disorders
  7. d-cycloserine Phase 2 · BRIGHT MINDS BIOSCIENCES · Panic Disorder
  8. d-cycloserine Phase 2 · BRIGHT MINDS BIOSCIENCES · COCAINE-RELATED DISORDERS
  1. US 12427199

    Self-assembled diblock copolymers composed of pegmema and drug bearing polymeric segments

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  2. US 12171822

    Infectious plasmodium sporozoites grown in vitro

    Expires Mon Dec 19 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  3. US 12129288

    Polynucleotides heterodimers of soluble interferon receptors and uses thereof

    Expires Mon Oct 24 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  4. US 12077543

    P2X3 and/or P2X2/3 compounds and methods

    Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  5. US 11939343

    Sting agonist compounds and methods of use

    Expires Mon Mar 21 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  6. US 11883475

    Infectious Plasmodium sporozoites grown in vitro

    Expires Mon Jan 25 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  7. US 11434278

    Protein-polymer-drug conjugates

    Expires Mon Sep 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  8. US 11339169

    P2X3 and/or P2X2/3 compounds and methods

    Expires Mon May 19 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  9. US 11207395

    Infectious plasmodium sporozoites grown in vitro

    Expires Mon Dec 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  10. US 11155567

    Sting agonist compounds and methods of use

    Expires Mon Oct 21 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  11. US 10947295

    Heterodimers of soluble interferon receptors and uses thereof

    Expires Mon Mar 11 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  12. US 10772971

    Methods of producing drug-carrying polymer scaffolds and protein-polymer-drug conjugates

    Expires Mon Sep 10 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  13. US 10660901

    Pyrrolobenzodiazepines and conjugates thereof

    Expires Mon May 21 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  14. US 10647720

    Pyrimido-pyridazinone compounds and methods of use thereof

    Expires Mon May 07 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  15. US 10611768

    P2X3 and/or P2X2/3 compounds and methods

    Expires Mon Apr 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  16. US 10603386

    Protein-polymer-drug conjugates

    Expires Mon Mar 26 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  17. US 10590127

    P2X3 and/or P2X2/3 compounds and methods

    Expires Mon Mar 12 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  18. US 10544145

    P2X3 and/or P2X2/3 compounds and methods

    Expires Mon Jan 23 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  19. US 10537645

    Protein-polymer-drug conjugates

    Expires Mon Jan 16 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted
  20. US 10526294

    Pyrrolobenzodiazepines and conjugates thereof

    Expires Mon Jan 02 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

What is cycloserine?

cycloserine (SEROMYCIN) is a alanine racemase inhibitor. Associated with Sana Biotechnology. Route of administration: oral. Current US regulatory status: approved.

What is the brand name for cycloserine?

SEROMYCIN is a marketed brand name for cycloserine. Check FDA Drugs@FDA for the current US label holder and prescribing information.

What is the US approval status of cycloserine?

cycloserine has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.